Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156487 | 0.90 | HTR2C (0.36) | HTR2CSLC6A4HDAC1HDAC6HDAC2 | |
| SCHEMBL1156621 | 0.90 | HTR2C (0.42) | HTR2CSLC6A4HTR6GLS | |
| SCHEMBL30089348 | 0.89 | HTR6 (0.40) | HTR2CSLC6A4HTR6RIPK1 | |
| SCHEMBL1156562 | 0.89 | HTR6 (0.40) | HTR2CSLC6A4HTR6RIPK1 | |
| SCHEMBL2416549 | 0.89 | RIPK1 (0.39) | HTR2CSLC6A4HTR6PKMRIPK1 | |
| SCHEMBL2407643 | 0.88 | CHRM5 (0.42) | HTR6HDAC1PKM | |
| SCHEMBL4411752 | 0.88 | HTR2C (0.41) | HTR2CSLC6A4HTR6GLS | |
| SCHEMBL31754845 | 0.87 | RORC (0.42) | HTR6 | |
| SCHEMBL29262658 | 0.86 | TNFSF11 (0.46) | L3MBTL1MMP2 | |
| SCHEMBL30894736 | 0.85 | HTR2C (0.38) | HTR2CSLC6A4HTR6GLSMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001864-A1 | COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION | NANJING SHUOHUI PHARMATECHNOLOGY CO., LTD (CN) | 2026-01-01 | — | — | US | disclosed |
| WO-2023284159-A1 | COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION | 南京烁慧医药科技有限公司 | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001864-A1 | COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION | SLC10A2, SLC6A11, ABCB11 | HTR2C 663/4885SLC6A4 79/4885HTR6 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.